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Introduction
Cardiovascular disease is the leading cause of mortality in this country. 1 Cardiac transplantation is an accepted and often the only treatment modality for end-stage heart failure. Unfortunately, the number of transplants performed is limited by both the size of the donor pool, which has remained fairly constant over the last few years 2 and by the fact that many potential organs have marginal functional status. Significant loss of function in donor hearts can be due to uncoupling of the ␤-adrenergic receptor (␤-AR) system where significant myocardial ␤-AR desensitization has been shown to occur after experimental brain death. 3 The ␤-AR system in the heart is one of the most powerful means for increasing cardiac contractility. Moreover, ventricular dysfunction associated with decreased ␤-AR signaling in brain death may represent a primary basis for post-operative graft failure. In fact, a major limitation of cardiac transplantation is the frequent need for aggressive inotropic support (ie ␤-AR agonists) to sustain early graft survival. 4 Importantly, ␤-AR down-regulation in the transplanted heart has been observed among patients suffering from intractable graft failure even in the absence of rejection. 4 Thus, in theory, if one could enhance the function of these marginal organs through the use of 'genetic manipulation', a great benefit would be realized. In addition to cardiac transplantation, perioperative dysfunction also frequently occurs in the setting of cardiopulmonary bypass which also requires aggressive inotropic therapy after surgery. 5 Therefore, in the cardiac surgery arena, genetic modulation of the ␤-AR system, even transiently, could result in an increase of baseline cardiac function perioperatively, decreasing the requirement for inotropic support. This novel genetic manipulation could potentially decrease the post-operative recovery time resulting in earlier discharge of the patient and ultimately decreasing hospital costs.
Altering the genetic content of cardiomyocytes within the heart is the goal of any cardiac gene therapy protocol. Typically, this is facilitated by vector-mediated addition of a foreign gene. There have been numerous reports, [6] [7] [8] [9] [10] including from this laboratory, 10 of successful gene transfer in animal models of cardiac transplantation. The majority of these studies have only demonstrated the feasibility of gene transfer using marker genes but they have shown efficient gene transfer to transplanted myocardium especially with adenoviral vectors. 7, 8, 10 Previous work from our laboratory has demonstrated that overexpression of the human ␤ 2 -AR in the hearts of transgenic mice leads to a state of heightened in vivo cardiac function. 11 Furthermore, adenovirus-mediated transfer of the ␤ 2 -AR gene to cultured adult cardiomyocytes has led to enhanced ␤-AR signaling and cAMP production. 12 Thus, the ability to transfer the ␤ 2 -AR transgene acutely to adult myocardium, especially during transplantation, could have significant therapeutic implications. In this report, we examine the functional effects of myocardial ␤ 2 -AR overexpression after adenovirusmediated gene transfer using a rat heterotopic heart transplant model.
Results
Histologic evaluation of donor rat hearts after injection of adenovirus and heterotopic transplantation The rat heart heterotopic transplantation model is well established and recently has been used to evaluate attempts to deliver transgenes to the myocardium. [6] [7] [8] [9] [10] We have previously shown that this model supports significant myocardial gene transfer which is global and myocyte-specific in nature using both marker transgenes (␤-galactosidase) and potentially therapeutic transgenes (human ␤ 2 -AR; Adeno-␤ 2 AR) via retrograde injection through the aortic root of saline solutions containing adenovirus. 10 In the present study, we assessed whether infusion of adenovirus leads to significant host immune response and myocardial damage in donor hearts which is a generalized phenomenon and potential limitation of adenovirus-mediated gene transfer. 13 Hematoxylin and eosin staining revealed that after 5 days, treated hearts appear quite healthy. There was minimal cellular infiltration and damage detected in either control untreated donor hearts or hearts treated with 1 × 10 10 p.f.u. in 1 ml of Adeno-␤ 2 AR solution ( Figure 1 ). We also examined random histological slices prepared from the lung and liver of the graft recipients and saw only healthy tissue (data not shown). Previously, we have shown that expression of adenoviral transgenes were limited to donor hearts with little inflammation present. 10 Human ␤ 2 -AR overexpression in donor rat hearts following intracoronary delivery of Adeno-␤ 2 AR Donor rat hearts that received 1 × 10 10 p.f.u. of Adeno-␤ 2 AR demonstrated a marked increase in global myocardial ␤-AR density compared with control hearts which were injected with the same amount of empty adenovirus containing no transgene (Adeno-MT) (Figure 2 ). ␤-AR density, as measured by radioligand binding and after basal physiological measurements (see below), showed an approximate six-fold increase 5 days after Adeno-␤ 2 AR delivery and transplantation ( Figure 2a ) compared with Adeno-MT-treated hearts which had native ␤-AR levels (407.7* ± 33.7 fmol/mg membrane protein versus 71.2 ± 13.9; n = 10 each group, *P Ͻ 0.02). Five days after transplantation and gene delivery was previously shown to be the time of peak transgene expression. 10 Competition binding isotherms of Adeno-␤ 2 AR treated donor hearts using the selective ␤ 2 -AR selective antagonist ICI 118,551 revealed that the increase in myocardial ␤-AR density was indeed exclusively due to ␤ 2 -AR overexpression (data not shown). Immunohistochemistry performed on ventricular sections of Adeno-␤ 2 -AR-injected hearts using antiserum specific for the human ␤ 2 -AR revealed sarcolemma-specific staining of myocytes which identifies cells infected with Adeno-␤ 2 AR (Figure 2b ). Adeno-MT treated hearts revealed no specific staining (data not shown) demonstrating the specificity of the antibody used. As shown in both longitudinal and cross sections (Figure 2b ), ␤ 2 -AR overexpression in myocytes was somewhat non-uniform in nature as infected cells exhibit different intensities of staining suggesting varying degrees of viral uptake.
Isolated cardiac function in ␤ 2 -AR overexpressing hearts following Adeno-␤ 2 AR injection Heterotopic transplanted rat hearts were explanted after 5 days as described above and ex vivo hemodynamic parameters were measured using a Langendorff isolated, isovolumic heart perfusion apparatus as described in Materials and methods. Importantly, at the time of explantation all hearts appeared to be in normal sinus rhythm. Heart rate and left ventricular end-diastolic pressure (LVEDP) were controlled for in each group by pacing at 280 beats per min (bpm) and establishing an LVEDP of 5 mmHg by means of an intraventricular saline-filled balloon. Baseline cardiac contractility, as measured by LV +dP/dt max , was doubled in Adeno-␤ 2 ARtreated hearts compared with hearts that received Adeno-MT ( Figure 3 ). Other cardiac functional parameters are listed in Table 1 . Significant baseline increases in LV −dP/dt min , as a measurement of cardiac relaxation, and mean LV systolic pressure (LVSP) were seen in the transplanted rat hearts treated with Adeno-␤ 2 AR. Following hemodynamic measurements, the isolated transplanted rat hearts were frozen and total ␤-AR density was 
u.) and heterotopic transplantation. Physiologic measurements in isolated hearts were done before freezing and ␤-AR radioligand binding. *, P Ͻ 0.02 versus Adeno-MT treated hearts (Student's t test). (b) Representative immunohistochemical detection of overexpressed human ␤ 2 -ARs, 5 days after Adeno-␤ 2 AR delivery to transplanted rat hearts. Shown are longitudinal (left) and cross (right) section of LV at low (top) and high (bottom) magnification. Staining is myocyte-specific and appears to be in the sarcolemmal membranes.
determined in myocardial membranes as shown in Figure 2a .
In a subset of isolated 5 day post-transplanted hearts, we perfused the ␤ 2 -AR agonist zinterol. Before zinterol administration, these specific hearts treated with Adeno-␤ 2 AR (n = 4) had significantly enhanced basal LV +dP/dt max (6780* ± 987 mmHg/s) versus hearts (n = 4) treated with Adeno-MT (3259 ± 496, *P Ͻ 0.05) which is similar to the values shown in Figure 3 . Following zinterol infusion (1 × 10 −7 m), Adeno-␤ 2 AR-treated hearts had a significantly greater contractility response compared with control donor hearts treated with Adeno-MT ( Figure 4 ) consistent with ␤ 2 -AR overexpression. Absolute contractility responses were not only greater in the Adeno-␤ 2 AR-treated hearts, but the change in LV +dP/dt max in response to zinterol was increased (+1980 mmHg/s) versus hearts treated with Adeno-MT (+1285 mmHg/s). Zinterol-induced LV −dP/dt min and LVSP values were also significantly greater in 5-day post-transplanted isolated rat hearts treated with Adeno-␤ 2 AR compared with control hearts as shown in Table 2 . In this group of transplanted rat hearts, ␤ 2 -AR overexpression after Adeno-␤ 2 AR delivery was similar to values in 
Discussion
Cardiac gene transfer to manipulate the genetic content of myocytes represents a novel therapeutic option in the treatment of cardiovascular disorders. Gene therapy applications in the future may include treatment of congestive heart failure, transplant dysfunction and rejection, perioperative dysfunction after cardiopulmonary bypass, as well as ischemic heart disease. The application of gene transfer to cardiac transplantation is especially appealing because of the direct access to the donor organ at the time of harvest. One could potentially transfer the foreign genetic material at that time and expression of the transgene could be evident within 12-24 h. Exogenous gene delivery to the donor organ at the time of harvest, can easily be accomplished with adenovirus as demonstrated in studies using mouse, rat and rabbit models. 7, 8, 10 The characteristic limited duration of transgene expression with adenoviral vectors would still provide significant benefit in the transplant setting during the critical perioperative period where there is frequent graft dysfunction and failure. 2, 4 Most studies dealing with adenovirus-mediated gene transfer to donor hearts have focused on the use and overexpression of marker genes, however, recently transgenes affecting the immune response of the host have been tested. 14, 15 There have been doubts about the use of adenovirus for cardiac gene transfer since early reports using direct injection of marker transgenes into the myocardium displayed expression limited to the needle tract and this method of delivery was further complicated by local inflammation. 16, 17 In vivo intracoronary delivery of adenoviral transgenes has been demonstrated, 18, 19 but on the whole is very difficult probably because of insufficient contact time between the adenovirus and the beating myocardium.
The transplantation model is unique in that it provides the mechanism to accomplish global myocardial gene transfer. 10 Firstly, adenoviral solution is injected into the aortic root providing access to the entire myocardium presumably via both right and left coronary arteries, which is important for targeting changes in global cardiac function. Furthermore, the method of delivery occurs ex vivo and limits or eliminates extraneous adenovirus infection of other organ systems which limits potential unwanted side-effects. One limitation we have found is that lower amounts of adenoviral gene transfer occur with hypothermia (data not shown) which is obviously important clinically. Our most efficient gene transfer occurs when the adenovirus solution is delivered immediately after removal of the heart at normothermia followed by bathing the heart with ice-cold saline until the recipient animal is prepared.
Previously using the marker gene ␤-galactosidase (␤-gal) and the ␤ 2 -AR transgene, we have demonstrated that this model of adenovirus-mediated gene transfer results in myocardial transgene expression that is myocyte-specific and global in nature. 10 Staining for ␤-gal expression revealed that a significant percentage of the ventricular myocytes were positive for transgene expression. 10 Furthermore, immunohistochemical staining in Adeno-␤ 2 AR-treated donor hearts revealed global overexpression of ␤-ARs which was observed in individual myocytes, 10 which was also seen in the current study. A time-course of transgene expression using Adeno-␤ 2 AR demonstrated that 5 days after transplantation was the time of peak transgene expression, however, significant ␤-AR overexpression was still evident after 10 days. 10 The primary physiologic mechanism for enhancement of myocardial function involves the stimulation of the myocardial ␤-AR system. ␤ 1 and ␤ 2 -ARs have been identified in rat, dog and human hearts and both receptor subtypes are involved in regulation of inotropic and chronotropic responses via functional coupling to the adenylyl cyclase system through the heterotrimeric G protein, Gs. 20 Our laboratory has recently reported that adenovirus-mediated gene transfer of ␤ 2 -ARs to normal and failing adult rabbit ventricular myocytes in culture leads to potentiation of ␤-adrenergic signaling including the restoration of ␤-AR signaling in myocytes isolated from rabbits in congestive heart failure where ␤-AR function is defective. 12, 21 This work in myocytes as well as the current study, was formulated after studies in transgenic mice found that cardiac-targeted overexpression of the human ␤ 2 -AR to a density Ͼ100-fold over native myocardial ␤-AR levels led to enhanced in vivo cardiac contractility. 11 Importantly, a recent report has demonstrated that lower levels of ␤ 2 -AR overexpression in the hearts of transgenic mice leads to a similar in vivo cardiac phenotype. 22 In both of these transgenic mouse models with varying amounts of ␤ 2 -AR overexpression, cardiac function was increased under basal conditions which is significant in the transplant setting due to denervation and the lack of sympathetic stimulation. Thus, the goal of the current study was to determine whether overexpression of the ␤ 2 -AR in transplanted rat myocardium could lead to global alteration of contractility, even in the absence of added inotropic agents.
In this study, using the heterotopic transplanted rat heart, we delivered 1 × 10 10 p.f.u. of Adeno-␤ 2 AR and 5 days later found global myocardial ␤-AR density to be significantly elevated and importantly, ␤ 2 -AR transgene delivery was to individual myocytes and expression was appropriately found in the sarcolemma. Interestingly, ␤ 2 -AR gene delivery did not lead to significant inflammation or cellular infiltration at least at 5-days after transplantation despite this being a common characteristic of in vivo adenovirus-mediated gene transfer. 13 The ␤-AR overexpression in grafted rat hearts in this study did not reach the proportion seen in transgenic mice, however, even with an approximate six-fold increase in ␤-AR density, there was a doubling of basal cardiac contractility as measured by LV +dP/dt max . Furthermore, stimulation with a ␤ 2 -agonist resulted in enhanced ␤-AR physiologic responsiveness, demonstrating that the ␤-ARs now overexpressed in the myocardium are functionally coupled to the appropriate inotropic pathways. The increased contractility following myocardial ␤ 2 -AR overexpression was demonstrated when compared with the function in hearts treated with an empty adenovirus. Injection of an empty adenovirus to the myocardium does not appear to alter contractility 23 and previously we have demonstrated that non-␤ 2 -AR containing adenoviruses did not alter the ␤-AR density of the transplanted rat heart. 10 Thus, the enhanced function of the ␤ 2 -AR overexpressing rat hearts is significant since it has been shown, using a murine model of heterotopic transplantation, that isografts without any intervention have reduced contractility. 24 Our data directly demonstrates that a potential application of ␤-AR gene transfer could be the augmentation of cardiac contractility in transplanted myocardium as demonstrated by the ex vivo gene transfer to the heart of ␤ 2 -ARs leading to enhanced cardiac performance basally and in response to ␤-agonism. This has significant clinical applicability as alterations in the ␤-AR system in transplanted hearts have been shown to be associated with decreased cardiac function post-operatively leading to poor prognosis. [24] [25] [26] [27] This includes loss of ␤-AR-mediated inotropic capacity of transplanted hearts 25 and defective ␤-AR-Gs-adenylyl cyclase coupling. 26, 27 This functional uncoupling is seen in transplanted hearts both without changes in ␤-AR density 24, 27 and receptor down-regulation, 4 suggesting that a six-fold increase in ␤-AR density as seen in this study is significant. Brain dead organ donors, some of whom have marginal hearts secondary to alterations in their ␤-AR system, 3 would also be potential candidates for genetic manipulation of their hearts in vivo thereby increasing the pool of viable, well-functioning hearts available for donation.
This study reports, for the first time, that exogenous gene transfer to an intact heart results in enhanced global cardiac function. This enhancement of cardiac function in transplanted myocardium through adenovirus-mediated gene transfer of the human ␤ 2 -AR demonstrates the potential usefulness of gene therapy strategies not only in the transplant setting but also in conditions of decreased cardiac function such as congestive heart failure. In the setting of heart failure, where there are documented abnormalities in the ␤-AR system, adenovirus-mediated transfer of transgenes encoding protein(s) that could restore normal signaling properties might produce unique inotropic benefits. ␤-AR gene transfer could also possibly be extended to cardiac surgery and cardiopulmonary bypass which may help in augmenting cardiac function in the perioperative period. In fact, in the post-operative setting following cardiopulmonary bypass, as in heart failure, studies have shown decreased or uncoupled ␤-ARs associated with decreased cardiac function. 5, 28 Indeed, a major focus of our laboratory effort is focused on the possibility of augmenting the performance of the heart in vivo through adenovirus-mediated gene delivery of ␤-ARs as well as an inhibitor of ␤-AR desensitization, in order to develop novel strategies to treat heart failure and other conditions of compromised heart function. 29 
Materials and methods

Recombinant adenovirus
The adenoviral backbone for Adeno-␤ 2 AR and Adeno-MT was a replication-deficient 'first-generation' Type V adenovirus with deletions of the E1 and E3 genes as we have previously described. 12, 21 Large-scale preparations of these adenoviruses were purified from infected EBNA transfected 293 cells (Invitrogen, San Diego, CA, USA) as described.
12, 21 The average titer of the Adeno-␤ 2 AR used in these studies was 2.69 × 10 10 p.f.u./ml with a viral particle to p.f.u. ratio of 43. There was detectable replication competent adenovirus (RCA) in 2.5 × 10 9 p.f.u. of Adeno-␤ 2 AR. The RCA assay was carried out by infecting HeLa cells with the test dose of Adeno-␤ 2 AR and then passaging a freeze-thaw lysate of the HeLa cell culture on to cultures of A549 cell as described. 30 At the lowest sensitivity this assay can detect at least 5 to 10 RCA genomes in a test dose of 1.25 × 10 8 p.f.u.
Heterotopic heart transplantation and adenovirus delivery All procedures and protocols were approved by the Animal Care and Use Committee of Duke University. Adult male Long Evans rats (250-300 g) were housed under standard conditions and fed a standard diet and water. All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health. Heterotopic intra-abdominal heart transplantation was performed using the technique as previously described by Ono and Lindsey 31 and modified by us. 10 Briefly, both donor and recipient underwent anesthesia with a mixture of ketamine (50 mg/kg) and xylazine (5 mg/kg). Donor rats were heparinized (300 U) and hearts were arrested with 5 ml of normothermic Roe's cardioplegia (20 mEq KCl, 27 mEq NaCl, 3 mEq MgSO 4 , 250 mg methylprednisolone sodium succinate and 2.25 mEq NaHCO 3 for a pH of 7.4). Cardiectomy was performed and a 1 ml saline solution of Adeno-␤ 2 AR or Adeno-MT (1 × 10 10 p.f.u.) was rapidly injected into the aortic root ex vivo. In the recipient animal, the infra-renal aorta and vena cava were exposed via a midline abdominal incision. An end-to-side anastomosis was performed between the donor and recipient aorta followed by an end-to-side anastomosis of the donor pulmonary artery to the recipient vena cava. All hearts resumed normal sinus rhythm within 5 min and total ischemic time was approximately 45 min. During transplantation, the heart was wrapped in gauze and kept at approximately 4°C through use of topical iced saline, although myocardial temperature was not measured. The adenovirus-containing solution was not flushed from the donor heart during the procedure and thus remained in the heart (45 min) until blood flow from the recipient rat was initiated. Abdomens were palpated daily to assure a functioning graft. Approximately 10% of all rats that underwent transplantation died within 24 h of surgery. Deaths were equally distributed among the different treatment groups. No animals died if they survived the first 24 h after transplantation. All hearts were in apparent normal sinus rhythm at time of explantation.
Histologic assessment and immunohistochemical labeling Transplanted myocardial tissue sections (two per heart; one from the apex and one from the base) were stained with hematoxylin and eosin by standard methods 10 and examined by light microscopy to detect and identify any structural changes, inflammatory reaction, or development of necrosis. For ␤ 2 -AR immunohistochemistry, 10 m frozen sections were prepared from transplanted rat hearts as described 10 and rinsed three times for 3 min each in phosphate-buffered saline solution (PBS) and 3 min in PBS with 0.05% Triton X-100 (Triton-PBS). The sections were then blocked with serum diluent (10% goat serum in PBS with 0.1% bovine serum albumin and 0.1% sodium azide) and rinsed for 15 min in Triton-PBS before overnight incubation at 4°C with rabbit polyclonal human ␤ 2 -AR antiserum 32 (1:500 dilution in serum diluent). The sections were then washed four times for 10 min each in Triton-PBS at room temperature and incubated for 1 h in fluorescein isothiocyanate-conjugated goat antirabbit immunoglobulin G (1:50 dilution in serum diluent). After five rinses in PBS, the sections were mounted with sodium iodide (25 gm/l) in 1:1 PBS/glycerol solution and photographed.
␤-AR binding assays
Membrane fractions were prepared from hearts and resuspended in binding buffer (75 mm Tris-HCl, pH 7.4/12.5 mm MgCl 2 /2 mm EDTA). Binding assays were performed on 25 g of membrane protein using saturating amounts of the ␤-AR-specific ligand 125 I-cyanopindolol (300 pm). Nonspecific binding was determined in the presence of 20 m alprenolol. Reactions were conducted in 500 l of binding buffer at 37°C for 1 h and terminated by vacuum filtration through glass-fiber filters. ␤ 1 and ␤ 2 subtype proportions were determined by competition with varying doses of the ␤ 2 -selective ligand ICI 118,551. All assays were performed in triplicate and receptor density (fmol) was normalized to milligrams of membrane protein. 10, 11, 21 Assessment of cardiac function Five days after heterotopic transplantation, animals were anesthetized with pentobarbital sodium (60 mg/kg) and heparinized (300 U). The transplanted hearts were excised and the aorta was rapidly cannulated. Hearts were perfused at a constant pressure (80 mmHg) in the Langendorff mode 33 with oxygenated (95% O 2 /5% CO 2 ) Krebs-Henseleit buffer solution at 37°C and a pH of 7.4 (containing in mmol/l: NaCl, 118; NaHCO 3 , 21; KCl, 4.7; KH 2 PO 4 , 1.2; MgSO 4 , 1.2; CaCl 2 , 2.5; EDTA, 0.25; dextrose, 11). The left atrium was cannulated with a fluid filled latex balloon attached to a high fidelity 5 French pressure transducer (Millar Instruments, Houston, TX, USA). The volume of the balloon was adjusted to achieve an end-diastolic pressure (LVEDP) of 5 mmHg for each heart. Hearts were paced at a rate of 280 bpm. Pressure was recorded with an analog to digital conversion and recording system (Labview, MacLab, Milford, MA, USA). Hearts were allowed to stabilize for 10 min before the collection of data which consisted of the following parameters; heart rate, LV systolic pressure (LVSP) and LV end diastolic pressure (LVEDP). The maximal rate of pressure rise in the LV (+dP/dt max ) and the rate of fall of LV (−dP/dt min ) were calculated by computer program (Labview, MacLab). As described, a subset of hearts done towards the end of the study were stimulated with the ␤ 2 -AR agonist zinterol (1 × 10 −7 m) after baseline measurements were recorded.
Statistical analysis
Quantitative data such as myocardial ␤-AR density following adenoviral transgene delivery and physiologic parameters are expressed as the mean ± s.e.m. The difference in the level of transgene expression and cardiac function between control and infected hearts was evaluated using a Student's t test. For all analyses, P Ͻ 0.05 was considered statistically significant.
